Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients.
Macrophage-colony stimulating factor, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 may play an important role in malignant processes. The aim of this study was to investigate the diagnostic power of those parameters (serological biomarkers) in comparison to cancer antigen 125 and squamous cell carcinoma antigen in cervical cancer patients and in relation to the control groups. The study included 100 cervical cancer patients, 50 patients with cervical ectropion and 50 healthy women. Plasma levels of tested parameters were determined by enzyme-linked immunosorbent assay, cancer antigen 125, and squamous cell carcinoma antigen by chemiluminescent microparticle immunoassay. Plasma levels of all parameters in the total cancer group showed statistical significance (in all cases p < 0.05). In stage I of cancer only medial supraclavicular fossa and tissue inhibitor of metalloproteinase-1, in stage II all the tested parameters and cancer antigen 125, and in stage III + IV macrophage-colony stimulating factor, matrix metalloproteinase-9, and cancer antigen 125 showed statistical significance when compared to the healthy volunteers group. Macrophage-colony stimulating factor showed the highest value of sensitivity from all tested parameters (I: 56.25%, II: 72.73%, III + IV: 77.14% and 69% in total cervical cancer group). The highest specificity was obtained by matrix metalloproteinase-9 (94%). Positive predictive values were highest also for matrix metalloproteinase-9 (I: 82.35%, II: 84.21%, III + IV: 88% and 94.55% in total cervical cancer group), negative predictive values for macrophage-colony stimulating factor (I: 75.44%, II: 82.69%, III + IV: 87.5% and 58.11% in total cervical cancer group) and tumor markers. In the total cervical cancer group, all tested parameters showed statistically significant areas under receiver operating characteristic curve, but maximum range was obtained for the combination macrophage-colony stimulating factor + squamous cell carcinoma antigen (0.8723). The combined analysis of tested parameters and tumor markers resulted in an increase in sensitivity and areas under receiver operating characteristic curve values, which provides hope for developing new panel of biomarkers that may be used in the diagnosis of cervical cancer in the future.
['Zajkowska|Monika|M|https://orcid.org/0000-0002-5179-0722', 'Zbucka-Krętowska|Monika|M|', 'Sidorkiewicz|Iwona|I|', 'Lubowicka|Emilia|E|', 'Gacuta|Ewa|E|', 'Szmitkowski|Maciej|M|', 'Chrostek|Lech|L|', 'Ławicki|Sławomir|S|']
D000230:Adenocarcinoma D000328:Adult D000951:Antigens, Neoplasm D014408:Biomarkers, Tumor D018394:CA-125 Antigen D002294:Carcinoma, Squamous Cell D016022:Case-Control Studies D005260:Female D005500:Follow-Up Studies D006801:Humans D016173:Macrophage Colony-Stimulating Factor D020780:Matrix Metalloproteinase 9 D008875:Middle Aged D011379:Prognosis D015843:Serpins D019715:Tissue Inhibitor of Metalloproteinase-1 D002583:Uterine Cervical Neoplasms D055815:Young Adult
Macrophage-colony stimulating factor matrix metalloproteinase-9 tissue inhibitor of metalloproteinase-1 cancer antigen 125 squamous cell carcinoma antigen